SCHEMBL4513381

SCHEMBL4513381

C[C@@H](COc1cccc2cnccc12)NS(=O)(=O)c1ccc(Cl)s1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 9/20 0.64
CYP3A4 P08684 3/20 0.42
CYP1A2 P05177 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
NFKBIA P25963 1/20 0.41
RELA Q04206 1/20 0.41
PRKD3 O94806 2/20 0.40
PRKCG P05129 2/20 0.40
PRKCB P05771 2/20 0.40
CYP2D6 P10635 2/20 0.40
PRKCA P17252 2/20 0.40
NFKB1 P19838 2/20 0.40
PRKCH P24723 2/20 0.40
PRKCI P41743 2/20 0.40
PRKCE Q02156 2/20 0.40
PRKCQ Q04759 2/20 0.40
PRKCZ Q05513 2/20 0.40
PRKCD Q05655 2/20 0.40
PRKD1 Q15139 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4510316 0.85 NR3C1 (0.68) NR3C1CYP3A4PRKD3PRKCGPRKCB
SCHEMBL4520346 0.82 NR3C1 (0.67) NR3C1CYP3A4CYP1A2CYP2C9CYP2C19
SCHEMBL4522810 0.80 NR3C1 (0.66) NR3C1CYP3A4PRKD3PRKCGPRKCB
SCHEMBL4512184 0.80 NR3C1 (0.72) NR3C1CYP3A4PRKD3PRKCGPRKCB
SCHEMBL4512055 0.79 NR3C1 (0.74) NR3C1KCNA3
SCHEMBL4516667 0.78 NR3C1 (0.56) NR3C1TP53
SCHEMBL4520415 0.78 NR3C1 (1.00) NR3C1
SCHEMBL4512135 0.77 NR3C1 (1.00) NR3C1CYP3A4PRKD3PRKCGPRKCB
SCHEMBL4506694 0.77 NR3C1 (0.85) NR3C1CYP3A4CYP2C19PRKD3PRKCG
SCHEMBL4508287 0.76 NR3C1 (0.72) NR3C1CYP3A4PRKD3PRKCGPRKCB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases ASTRAZENECA AB (SE) 2009-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090093485-A1 Novel Sulphonamide Derivatives as Glucocorticoid Receptor Modulators for the Treatment of Inflammatory Diseases NR3C1, NR3C2, NR5A1 NR3C1 1/4885CYP3A4 887/4885CYP1A2 1231/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.